ArticleCell reports2018
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 107 citations in OpenAlex.
- A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma.Cancer research · 2026Article
- Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.Melanoma research · 2026Review
- Novel CRISPR-Cas9 BAP1 knockout pre-clinical tumor model recapitulates human melanoma tumorigenesis and immune evolution.Communications biology · 2026Article
- The latestExpert opinion on drug discovery · 2026Review
- A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma.Molecular therapy. Oncology · 2026Article
- Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.Frontiers in oncology · 2026Review
- Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma.Biomolecules · 2025Article
- A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma.bioRxiv : the preprint server for biology · 2025Article
- The guanine nucleotide exchange factor Ric-8A regulates the sensitivity of constitutively active Gαq to the inhibitor YM-254890.The Journal of biological chemistry · 2025Article
- Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement.Progress in retinal and eye research · 2025Review
- Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters.Nature genetics · 2025Article
- R183Q GNAQ Sturge-Weber syndrome Leptomeningeal and Cerebrovascular Developmental Mouse Model.Journal of vascular anomalies · 2024Article
- Genetic Features of Uveal Melanoma.Genes · 2024Review
- Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated GMolecular pharmacology · 2024Review
- The role of signaling pathways mediated by the GPCRs CysLTR1/2 in melanocyte proliferation and senescence.Science signaling · 2024Review
- Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation.NPJ systems biology and applications · 2024Article
- Article
- Review
- Sturge-Weber syndrome: updates in translational neurology.Frontiers in neurology · 2024Review
- PAK1 and Therapy Resistance in Melanoma.Cells · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 4 institutions in 3 countries.
Amanda R MooreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, Cornell University, 1300 York Avenue, New York, NY 10065, USA.
Leili RanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Youxin GuanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Jessica J SherHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Tyler D HitchmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Jenny Q ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Catalina HwangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Edward G WalzakHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Sébastien MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, 1275 York Avenue, New York, NY 10065, USA.
Rajmohan MuraliDepartment of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, NY 10065, USA.
Thomas WiesnerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Klaus G GriewankDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium, Essen, Germany.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Electronic address: chip@mskcc.org.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Electronic address: cheny1@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · USDeutschen Konsortium für Translationale Krebsforschung · DEMedical University of Vienna · AT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MSPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC · 2010 to 2014
$11.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MAn integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MElucidating the roles of ETV1 in the pathogenesis of GISTK08CA151660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2011 to 2015
$848kUnderstanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796kNCI NIH HHS DP2 CA174499NCI NIH HHS K08 CA140946NCI NIH HHS K08 CA151660NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100
Abstract
Uveal melanoma (UM) is characterized by mutually exclusive activating mutations in GNAQ, GNA11, CYSLTR2, and PLCB4, four genes in a linear pathway to activation of PLCβ in almost all tumors and loss of BAP1 in the aggressive subset. We generated mice with melanocyte-specific expression of GNA11
Indexed as
Signal TransductionAnimalsCell LineageCell Line, TumorCell ProliferationCentral Nervous System NeoplasmsDisease Models, AnimalFemaleGTP-Binding Protein alpha SubunitsHumansMaleMelanocytesMelanomaMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesNeoplasm InvasivenessBAP1 protein, mouseGNA11 protein, mouseGTP-Binding Protein alpha SubunitsMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesProtein Kinase InhibitorsRasGRP3 protein, mouseras Guanine Nucleotide Exchange FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1BRAFgenetically engineered mouse modelGNA11GNAQleptomeningeal melanocytomamelanomaRASGRP3uveal melanoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.